Bloomfield, New Jersey Clinical Trials

A listing of Bloomfield, New Jersey clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 42 clinical trials
Test

In this prospective cohort study, 250 patients with suspected or known CAD and at least one intermediate coronary lesion (50-70% stenosis) who had a NiFFR value greater than 0.80 underwent coronary computed tomography angiography (CCTA) with NiFFR assessment. Patients were followed for one year to monitor for MACE

Online studies
  • 0 views
  • 28 Aug, 2025
  • Online study
Social & QoL Behaviors in Parkinson's Disease

Adults with Parkinson's Disease experience an array of challenges and changes in daily living, behaviors, and functioning throughout the progression of their condition. The investigators want to learn more about the effects of Parkinson's Disease on individuals' social behavior and quality of life (QoL) compared to people of the same …

Online studies
Accepts healthy volunteers
  • 0 views
  • 02 Apr, 2026
  • Online study
Study in Subjects With Relapsed/Refractory Follicular Lymphoma

This is a multicenter, double-blind, active-controlled, randomized, 3-stage, biomarker enrichment design featuring early futility stopping and sample-size re-estimation with safety run-in designed to evaluate the efficacy and safety of tazemetostat in combination with R2 in subjects with R/R FL, who have completed at least 1 prior systemic chemotherapy, immunotherapy, or …

hepatitis b surface antigen
renal function test
monoclonal antibodies
cancer therapy
lymphoma
Hackensack University Medical John Theurer Cancer Center
 (9.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +7 other locations
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine Cyclophosphamide and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab (FCR/BR) in FIT participants (FIT is defined by a cumulative illness rating scale [CIRS]/score of 6 and a normal creatinine clearance of 70 mL/min) …

lymphocytic leukemia
17p deletion
bendamustine
bone marrow procedure
rituximab
Regional Cancer Care Associates
 (9.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +50 other locations
Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Primary Objective: To determine whether SAR439859 per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer. Secondary Objectives: To compare the overall survival in the 2 treatment arms To assess the objective …

immunological adjuvant
breast cancer
letrozole
exemestane
cancer
Investigational Site Number 8400025
 (9.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +130 other locations
Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) Before and During Treatment With Ocrelizumab

This is an open-label, multicenter study that includes a main study for all participants enrolled and an optional cerebrospinal fluid (CSF) sub-study. Self-identified African American (AA) and Hispanic or Latin American (HA) participants with a diagnosis of relapsing multiple sclerosis (RMS) will be enrolled. The treating neurologist must make an …

Hackensack University Medical Center
 (9.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +30 other locations
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

This is a global, Phase 1/2, multicenter, open-label study. The clinical study will include of Phase 1: Dose Escalation (non-randomized, dose finding study) and Phase 2: Dose Expansion (randomized efficacy exploration). For Phase 1, the purpose of this study is to assess the maximum tolerated dose (MTD), recommend phase 2 …

glioblastoma multiforme
renal function test
MRI
recurrent disease
measurable disease
Hackensack Meridian Health, 92 Second Street
 (9.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

bethesda assay
antihemophilic factor
factor ix
hemophilia
fitusiran
Investigational Site Number 8400008
 (9.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
Multi-center Open-label Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Primary Objectives: To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) To evaluate the pharmacokinetics (PK) of SC and IV isatuximab Secondary Objectives: To estimate absolute bioavailability of SC and IV isatuximab To measure receptor occupancy (RO) after isatuximab SC versus IV administration To assess …

hepatitis b surface antigen
hbv dna
dexamethasone
arginine hydrochloride
antibiotic therapy
Investigational Site Number 8400006
 (9.4 away) Contact site
  • 0 views
  • 24 Nov, 2025
  • +13 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

bethesda assay
antihemophilic factor
factor ix
hemophilia
fitusiran
Investigational Site Number 8400008
 (9.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations